Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt(Dana-Farber Cancer Institute), Thomas Powles(Queen Mary University of London), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Yi Shi(Huzhou University), Peter H. O’Donnell(University of Chicago), Nicole N. Davarpanah(La Roche College), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Michiel S. van der Heijden(Zorginstituut Nederland), Daniel M. Geynisman(Fox Chase Cancer Center), Maha Hussain(Northwestern University), Jean Hoffman‐Censits(Sidney Kimmel Comprehensive Cancer Center), Siamak Daneshmand(Unknown), Cora N. Sternberg(Cornell University), Alexandra Drakaki(University of California, Los Angeles), Daniel P. Petrylak(Yale University), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Martin Majchrowicz, Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Jürgen E. Gschwend(Institut für Arbeitsmarkt und Berufsforschung), Peter Albers(Düsseldorf University Hospital), Hiroyuki Nishiyama(University of Tsukuba), Jens Bedke, Viraj Degaonkar(La Roche College), Yousef Zakharia(University of Iowa), Arash Rezazadeh Kalebasty(University of California, Irvine)
Cited by 411
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k